Innate Pharma SA (OTCMKTS:IPHYF) Short Interest Update

Key Points

• Innate Pharma SA experienced a significant 73.6% decrease in short interest during September, with totals dropping from 11,000 to 2,900 shares.
• The stock price remained stable at $2.00, with a one-year low of $1.31 and a high of $2.06, indicating limited volatility.
• Innate Pharma is engaged in developing immunotherapies for cancer, with several products currently in various phases of clinical trials targeting multiple cancers.

Innate Pharma SA (OTCMKTS:IPHYF - ) was the target of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 2,900 shares, a decrease of 73.6% from the September 15th total of 11,000 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Innate Pharma Stock Performance

OTCMKTS IPHYF remained flat at $2.00 on Friday. Innate Pharma has a 1 year low of $1.31 and a 1 year high of $2.06. The stock's 50 day moving average is $2.01 and its 200 day moving average is $1.71.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.